Home LiteratureArticle Details
PMID: 23406767 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Study of ABCB1 polymorphism frequency in breast cancer patients from Poland.

Pharmacological reports : PR ·Vol. 64 ·No. 6 ·2012-00-00 ·页码 1560-6

Rubiś B, Hołysz H, Barczak W, Gryczka R, Łaciński M, Jagielski P, Czernikiewicz A, Półrolniczak A, Wojewoda A, Perz K, Białek P, Morze K, Kanduła Z, Lisiak N, Mrozikiewicz PM, Grodecka-Gazdecka S, Rybczyńska M

Abstract

The accumulation of mutagenic substances in the human body may result in DNA metabolism disruption followed by carcinogenesis. As a consequence of mutations in the genes coding for transmembrane protein pumps, the intracellular concentration of xenobiotics may significantly increase. This, in turn, may provoke altered risk for cancer development. The gene known to be the most relevant in the transport of numerous compounds is ABCB1 (also known as MDR1). Numerous mutations and polymorphisms that affect the encoded protein's (PgP) function were identified in this gene. The aim of the study was to define the frequency of 2677G>A,T and 3435C>T polymorphisms in a population of Polish breast cancer patients and to estimate their contribution to cancer development. The polymorphism frequency analysis (209 patients vs. 202 control subjects) was performed either by allele-specific amplification (2677G>A,T) or by restriction fragment length polymorphism (RFLP) using the SAU3AI restriction enzyme (3435C>T) followed by verification with hybridization probe assays in a Real-Time system and sequencing. In the control group the frequency of individual 2677 genotypes was: wild homozygous GG = 34%, heterozygous G/T or G/A = 52.5% and variant homozygous AA or TT = 13.5%, while the genotype frequency in the group of studied patients was 43.5, 44.5 and 12%, respectively. In the control group, the frequency of individual 3435 genotypes was: CC = 25.4%, CT = 50.2%, TT = 24.4%, while the genotype frequency in the group of studied patients was 23, 46 and 31%, respectively. Thus, no significant differences in the studied polymorphism frequencies were observed. It is then suggested that the studied polymorphisms, although probably good candidates in other tissue cancer types, might not be good predictive factors in breast cancer risk or development in Caucasians.

MeSH 主题词
ATP Binding Cassette Transporter, Subfamily B ATP Binding Cassette Transporter, Subfamily B, Member 1/genetics Aged Amplified Fragment Length Polymorphism Analysis Breast Neoplasms/epidemiology,genetics,pathology Case-Control Studies Chi-Square Distribution Female Gene Frequency Genetic Predisposition to Disease Heterozygote Homozygote Humans Middle Aged Odds Ratio Phenotype Poland/epidemiology Polymorphism, Genetic Polymorphism, Restriction Fragment Length Prognosis Real-Time Polymerase Chain Reaction Risk Factors Sequence Analysis, DNA/methods
化学物质
ABCB1 protein, human ATP Binding Cassette Transporter, Subfamily B ATP Binding Cassette Transporter, Subfamily B, Member 1
作者与单位
共 17 位作者,点击展开单位 / ORCID
Rubiś Błażej
Poznań Department of Clinical Chemistry and Molecular Diagnostics, Poznań University of Medical Sciences, Przybyszewskiego 49, PL 60-355 Poznań, Poland.
Hołysz Hanna
Barczak Wojciech
Gryczka Robert
Łaciński Mariusz
Jagielski Paweł
Czernikiewicz Anna
Półrolniczak Anna
Wojewoda Aneta
Perz Katarzyna
Białek Paweł
Morze Karolina
Kanduła Zuzanna
Lisiak Natalia
Mrozikiewicz Przemysław M
Grodecka-Gazdecka Sylwia
Rybczyńska Maria
Article Info
Journal
Pharmacological reports : PR
Abbr.
Pharmacol Rep
ISSN
1734-1140
Published
2012-00-00
页码
1560-6
Language
English
Country/Region
Switzerland
NLM ID
101234999
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]